Alzheimer's disease profoundly affects memory and brain function in older individuals. The disease starts slowly and worsens to the extent that people eventually need 24-hour care - a heart-breaking, exhausting and often costly reality for family and health services. With an ageing population, Alzheimer's disease care provision needs will increase with an impact on NHS healthcare costs. In this study we will investigate whether losartan, a well-tolerated blood pressure drug, can complement current therapies for Alzheimer's disease. We believe losartan will slow down the progression of Alzheimer's disease by improving brain blood flow and altering chemical pathways that affect abnormal proteins that accumulate in Alzheimer's disease and cause brain shrinkage. This study tests the effect of losartan on brain tissue changes in patients diagnosed with Alzheimer's disease.
|Effective start/end date||1/03/13 → 31/07/19|